Stocks and Investing
Stocks and Investing
Mon, October 14, 2019
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Fri, October 11, 2019
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Matthew Harrison Maintained (BIIB) at Sell with Increased Target to $212 on, Oct 11th, 2019
Matthew Harrison of Morgan Stanley, Maintained "Biogen Inc." (BIIB) at Sell with Increased Target from $211 to $212 on, Oct 11th, 2019.
Matthew has made no other calls on BIIB in the last 4 months.
There are 2 other peers that have a rating on BIIB. Out of the 2 peers that are also analyzing BIIB, all agree with Matthew's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Sumant Kulkarni of "Canaccord Genuity" Maintained at Hold with Increased Target to $285 on, Wednesday, July 24th, 2019
- Christopher Raymond of "Piper Sandler" Downgraded from Buy to Hold and Decreased Target to $250 on, Friday, June 28th, 2019
Contributing Sources